Solutia Reports Third Quarter 20...(nterest expense income taxes depreciatio...)

Date:10/26/2009

nterest expense, income taxes, depreciation and amortization, less net income attributable to non-controlling interests, and reorganization items, net. Foreign currency gains/losses are included in Unallocated and Other. (2) Adjusted EBITDA is EBITDA (as defined above), excluding Adjustments (as defined below) (3) Adjustments include Events Affecting Comparability (see separate table), cost overhang associated with the sale of the Integrated Nylon business, and non-cash stock compensation expense Consolidated and segment sales, EBITDA(1) and Adjusted EBITDA(3) nine months ended September 2009 and 2008 Nine Months Ended September 30 From Continuing Adjust- 2009 Adjust- 2008 Operations ments As ments As % (in millions) 2009 (3) Adjusted 2008 (3) Adjusted change ---- ----- -------- ---- ------ -------- ------ Net Sales Saflex $475 $475 $634 $634 -25% CPFilms 141 141 196 196 -28% Technical Specialties 566 566 821 821 -31% Unallocated and Other 15 15 30 30 -50% --- --- --- --- --- Total $1,197 $1,197 $1,681 $1,681 -29% ===== ===== ===== ===== === EBITDA(1) Saflex $99 $11 $110 $71 $37 $108 2% CPFilms 24 4 28 43 10 53 -47% Technical Specialties 190 (14) 176 165 27 192 -8% Unallocated and Other (73) 30 (43) (29) (4) (33) 30% ---
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009